Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | WNT1 | P04628 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12547481 | 0.88 | MAP4K1 (0.44) | MAP4K1METNQO2FFAR1NEK2 | |
| SCHEMBL1296276 | 0.85 | MET (0.57) | MAP4K1METNQO2CHRM3 | |
| SCHEMBL12547054 | 0.82 | HPGDS (0.48) | — | |
| SCHEMBL1581330 | 0.77 | MET (0.59) | METNQO2 | |
| SCHEMBL1581704 | 0.77 | JAK2 (0.48) | MAP4K1METACVR1 | |
| SCHEMBL14641623 | 0.76 | MET (0.42) | METNQO2ACVR1 | |
| SCHEMBL22310395 | 0.76 | FYN (0.51) | METDYRK1AS1PR1 | |
| SCHEMBL3092459 | 0.75 | MET (0.63) | METNQO2 | |
| SCHEMBL3088753 | 0.75 | MET (0.67) | METNQO2 | |
| SCHEMBL3091030 | 0.75 | MET (0.62) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2310013-B1 | BICYCLIC TRIAZOLE DERIVATIVES FOR TREATING TUMORS | MERCK PATENT GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-8435986-B2 | Bicyclic traizole derivatives for treating of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8435986-B2 | Bicyclic traizole derivatives for treating of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-06-09 | — | — | US | disclosed |
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG | 2011-06-09 | — | — | US | disclosed |
| WO-2010017870-A1 | BICYCLIC TRIAZOLE DERIVATIVES FOR TREATING TUMORS | MERCK PATENT GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135600-A1 | BICYCLIC TRAIZOLE DERIVATIVES FOR TREATING OF TUMORS | RET, BMX, ERBB2 | MAP4K1 733/4885MET 11/4885NQO2 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.